Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study

Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries

(2019) Nataliya Volkova et al.   Journal of Cystic Fibrosis

Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D - CFTR mutation treated with ivacaftor

(2018) Patrick A. Flume et al.   Journal of Cystic Fibrosis

Do cystic fibrosis centres with the lowest FEV 1 still use the least amount of intravenous antibiotics? A registry-based comparison of intravenous antibiotic use among adult CF centres in the UK

(2018) Zhe Hui Hoo et al.   Journal of Cystic Fibrosis

Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data

(2015) Gregory S. Sawicki et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor

(2015) Christopher M. Siracusa et al.   Journal of Cystic Fibrosis

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST)

(2014) Edward F McKone et al.   Lancet Respiratory Medicine

Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with aG551DMutation

(2013) Jane C. Davies et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week-days during school term-time

(2013) Rosemary Ball et al.   Journal of Cystic Fibrosis

Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis

(2013) Samya Z. Nasr et al.   JOURNAL OF MEDICAL ECONOMICS

Longitudinal association between medication adherence and lung health in people with cystic fibrosis

(2011) Michelle N. Eakin et al.   Journal of Cystic Fibrosis

A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation

(2011) Bonnie W. Ramsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung function decline from adolescence to young adulthood in cystic fibrosis

(2011) Stacy L. VandenBranden et al.   PEDIATRIC PULMONOLOGY

Adherence with tobramycin inhaled solution and health care utilization

(2011) Becky A Briesacher et al.   BMC Pulmonary Medicine

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutation

(2010) Frank J. Accurso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis

(2009) Paul S. McNamara et al.   Journal of Cystic Fibrosis